AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2903191
Drug: Unchanged antihypertensive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unchanged antihypertensive treatment.
Trial: 22890369
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone (IVTA) 4 mg/0.1 mL
Trial: 19809604
Drug: Pharmacologic thromboprophylaxis
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic thromboprophylaxis with low‐molecular‐weight heparins, vitamin K antagonists, or fondaparinux
Trial: 16996338
Drug: L-EUS
RxNorm normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-EUS
Trial: 14584962
Drug: Deramciclane 30
RxNorm normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deramciclane 30 mg intravenous administration
Trial: 14584962
Drug: Deramciclane oral
RxNorm normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deramciclane oral administration (solution)
Trial: 14584962
Drug: Deramciclane oral
RxNorm normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deramciclane oral administration (tablet)
Trial: 7599448
Drug: Fluoride treatment
RxNorm normalized name: 60 Second 1.23% Fluoride Treatment Dental Gel
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoride treatment (75 mg NaF/day)
Trial: 360272
Drug: Lidocaine administered
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine administered as a bolus intra-arterially prior to contrast media injections
Trial: 360272
Drug: Lidocaine mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine mixed with contrast agent (2 mgm of lidocaine with each ml of contrast agent)
Trial: 30824252
Drug: Tablet-facilitated TF-CBT
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet-facilitated TF-CBT
Trial: 28382880
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no adjunctive maneuvers)
Trial: 25223583
Drug: CPX-351 (cytarabine:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPX-351 (cytarabine: daunorubicin) liposome injection
Trial: 25223583
Drug: Control salvage
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control salvage treatment (investigators' choice of first salvage chemotherapy)
Trial: 15370939
Drug: Preparation/Action stages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation/Action stages of change
Trial: 11349750
Drug: Overall relationship
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall relationship between prescription orders filled/hour and risk of dispensing errors
Trial: 23559219
Drug: Atypical antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotic exposure
Trial: 23559219
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antipsychotic exposure)
Trial: 20622680
Drug: Intermittent Sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Sequential Compression Device (SCD)
Trial: 19531453
Drug: Bioimmunochemotherapy (BCT)
RxNorm normalized name: Pegylated recombinant human arginase i bct-100
DrugBank: Pegylated Recombinant Human Arginase I (DB16282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioimmunochemotherapy (BCT) with cisplatin 20 mg/m² i.v. days 1,4; dacarbazine 800 mg/m² i.v. day 1; vinblastine 1.5 mg/m² i.v. days 1,4; IL-2 9 MIU/m² s.c. days 5,8; IFN-alpha-2b 5 MIU/m² s.c. days 5,8,11,13,15; supported by G-CSF and antibiotics
Trial: 9783758
Drug: Meloxicam (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (7.5 mg once daily for 28 days)
Trial: 9783758
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg once daily for 28 days)
Trial: 28042979
Drug: L-PRF and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PRF and BMP-2
Trial: 25076119
Drug: Prehospital TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital TXA infusion
Trial: 16375658
Drug: 1,000 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg/day of divalproex sodium
Trial: 16375658
Drug: 1,500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 mg/day of divalproex sodium
Trial: 11973443
Drug: Transdermal E2/LNG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2/LNG (E2 0.045 mg/day with 0.030 and 0.040 mg/day LNG)
Trial: 11973443
Drug: Transdermal E2/LNG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2/LNG (E2 0.045 mg/day with 0.015, 0.030, and 0.040 mg/day LNG)
Trial: 11973443
Drug: Transdermal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2 0.045 mg/day
Trial: 11973443
Drug: Transdermal E2/LNG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2/LNG and E2
Trial: 11973443
Drug: Transdermal E2/LNG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2/LNG
Trial: 2478428
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with cisplatin, vinblastine, and bleomycin (PVB)
Trial: 2478428
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant treatment (refused adjuvant therapy)
Trial: 2478428
Drug: Low-risk group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-risk group (no specific treatment mentioned)
Trial: 2478428
Drug: High-risk group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk group (no specific treatment mentioned)
Trial: 30229847
Drug: Hydromorphone intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone intravenous analgesia
Trial: 30229847
Drug: Morphine intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine intravenous analgesia
Trial: 16086617
Drug: Risperidone (1-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (1-6 mg/day)
Trial: 11099601
Drug: Methacholine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine inhalation challenge (group N-A)
Trial: 11099601
Drug: Methacholine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine inhalation challenge (group N-N)
Trial: 11099601
Drug: Methacholine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine inhalation challenge (group A-A)
Trial: 27221806
Drug: Dapagliflozin added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin added to metformin
Trial: 27221806
Drug: Dipeptidyl-peptidase-4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipeptidyl-peptidase-4 inhibitor (DPP-4i)
Trial: 20812339
Drug: Prednisolone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (20 mg/day for 14 days)
Trial: 10617012
Drug: EACA (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EACA (5 g bolus, 2 g/h infusion, 2.5 g in priming)
Trial: 10617012
Drug: TA (1
RxNorm normalized name: {56 (elexacaftor 100 MG / ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet) / 28 (ivacaftor 150 MG Oral Tablet) } Pack [Trikafta (100 MG / 50 MG / 75 MG; 150 MG)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA (1 g bolus, 400 mg/h infusion, 500 mg in priming)
Trial: 10617012
Drug: AP (280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP (280 mg bolus, 70 mg/h infusion, 280 mg in priming)
Trial: 1985413
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (20 mg/kg im soon after birth, and at 24 and 48 hours)
Trial: 1985413
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (single dose of 20 mg/kg)
Trial: 6189581
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy for cerebral metastases
Trial: 6189581
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy for headaches
Trial: 6189581
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy for convulsions
Trial: 6189581
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy for motor loss
Trial: 6189581
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy for bone metastases in prostatic carcinoma
Trial: 6189581
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy for bone metastases in renal primaries
Trial: 6189581
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy for pain relief at eight weeks
Trial: 6189581
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy for total group of patients
Trial: 21339433
Drug: Casopitant plus
RxNorm normalized name: casopitant
DrugBank: Casopitant (DB06634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casopitant plus ondansetron (oral casopitant 50 mg + intravenous ondansetron 4 mg)
Trial: 21339433
Drug: Ondansetron only
RxNorm normalized name: Ondansetron only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron only (intravenous ondansetron 4 mg)
Trial: 19900234
Drug: Amitriptyline 50
RxNorm normalized name: amitriptyline 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 50 mg at night
Trial: 15354947
Drug: Pulse intravenous
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse intravenous cyclophosphamide
Trial: 17066740
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral cyclophosphamide
Trial: 10651841
Drug: rhEPO plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO plus intravenous iron sucrose (group 1)
Trial: 10651841
Drug: rhEPO placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO placebo plus intravenous iron sucrose (group 2)
Trial: 10651841
Drug: oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral iron alone (group 3)
Trial: 9580102
Drug: Isoxsuprine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoxsuprine (50 mg in 250 ml of DW5%)
Trial: 8160562
Drug: Cetirizine 20
RxNorm normalized name: cetirizine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 20 mg (10 mg twice a day)
Trial: 3511182
Drug: Urabe Am
RxNorm normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Urabe Am 9‐Schwarz vaccine
Trial: 3511182
Drug: Jeryl Lynn‐Moraten
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jeryl Lynn‐Moraten vaccine
Trial: 27470259
Drug: Supportive-expressive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive group (SEG) therapy
Trial: 15188939
Drug: Hypertensive patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertensive patients receiving contemporary medical therapy
Trial: 15188939
Drug: Non-hypertensive patients
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-hypertensive patients receiving contemporary medical therapy
Trial: 12363115
Drug: Aripiprazole 15
RxNorm normalized name: aripiprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 15 mg/day and Haloperidol 10 mg/day
Trial: 7947240
Drug: rHuEPO (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO (200 units/kg intravenous bolus daily) for 28 days or until Hct of 35% reached
Trial: 3332575
Drug: Nifedipine GITS,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS, 30 or 60 mg daily
Trial: 3332575
Drug: Hydrochlorothiazide, 25
RxNorm normalized name: HydroCHLOROthiazide, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide, 25 or 50 mg daily
Trial: 11739337
Drug: Pharmaceutical industry
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical industry support
Trial: 24697872
Drug: Oral terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbinafine for 2 weeks and topical terbinafine and 10% urea ointment for 4 weeks
Trial: 24697872
Drug: Topical terbinafine
RxNorm normalized name: terbinafine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical terbinafine and 10% urea ointment for 12 weeks
Trial: 18271228
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (needling method at Baihui (GV 20), Shenting (GV 24), Shenmen (HT 7))
Trial: 10102158
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin (HDIVIG) therapy (1 g kg(‐1), over 4 h) with phototherapy
Trial: 2197716
Drug: multimodal hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multimodal hospital treatment without IFI
Trial: 2197716
Drug: multimodal hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multimodal hospital treatment with IFI
Trial: 21504
Drug: HC 20‐511
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HC 20‐511 4 mg daily
Trial: 21504
Drug: HC 20‐511
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HC 20‐511 2 mg daily
Trial: 21504
Drug: Cyproheptadine (Periactin)
RxNorm normalized name: cyproheptadine hydrochloride Oral Solution [Periactin]
DrugBank: Cyproheptadine (DB00434)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyproheptadine (Periactin) 8 mg daily
Trial: 24734908
Drug: Setipiprant 2000
RxNorm normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setipiprant 2000 mg single dose
Trial: 24734908
Drug: Setipiprant 500
RxNorm normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setipiprant 500 mg b.i.d. for 5.5 days
Trial: 24734908
Drug: Setipiprant 1000
RxNorm normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setipiprant 1000 mg b.i.d. for 5.5 days
Trial: 24734908
Drug: Setipiprant (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setipiprant (single and multiple doses)
Trial: 24734908
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of unchanged setipiprant
Trial: 15001199
Drug: Perindopril 2
RxNorm normalized name: perindopril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 2 mg plus Indapamide 0.625 mg
Trial: 15187802
Drug: Pemoline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemoline (75 to 112.5 mg, titrated over 4 weeks to a single morning dose for 12 weeks)
Trial: 11328223
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg mifepristone followed by gemeprost 1 mg vaginally
Trial: 11328223
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg mifepristone followed by gemeprost 1 mg vaginally
Trial: 7955441
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month)
Trial: 25818264
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of collagenase Clostridium histolyticum (CCH) 0.58 mg
Trial: 24340995
Drug: HyperHAES solution
RxNorm normalized name: Hyperhep B Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HyperHAES solution used during prolonged veno-venous haemofiltration
Trial: 12955428
Drug: Subcutaneous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous octreotide administered 1 hour before stenting and every 8 hours for 3 weeks
Trial: 12955428
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 1 hour before stenting and every 8 hours for 3 weeks
Trial: 12955428
Drug: Subcutaneous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous octreotide
Trial: 29973117
Drug: Education with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education with fluorescent gel
Trial: 28323043
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin D3 (20,000 IU twice a week)
Trial: 28323043
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (placebo)
Trial: 27411750
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and alternative medicine (CAM) use at baseline
Trial: 27411750
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and alternative medicine (CAM) use at 52 weeks
Trial: 23107894
Drug: Carvedilol (C,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (C, 20 then 40 mg/day)
Trial: 23107894
Drug: Valsartan (V,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (V, 160 then 320 mg/day)
Trial: 7398983
Drug: Local application
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of hair lotions with 17 alpha-estradiol (0.025%)
Trial: 7398983
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (hair lotions without 17 alpha-estradiol)
Trial: 26463318
Drug: ODM-201 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODM-201 (600 mg dose in capsules and tablets)
Trial: 26463318
Drug: ODM-201 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODM-201 (600 mg twice daily in capsules)
Trial: 23135530
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine 0.05% (group A)
Trial: 20813689
Drug: Oxymatrine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymatrine (150 mg daily, intravenously)
Trial: 20813689
Drug: Gluthion (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluthion (1.2 g daily, intravenously)
Trial: 8201768
Drug: SY5555 dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY5555 dry syrup at 3 mg/kg
Trial: 8201768
Drug: SY5555 dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY5555 dry syrup at 5 mg/kg
Trial: 8201768
Drug: SY5555 dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY5555 dry syrup at 10 mg/kg
Trial: 8201768
Drug: SY5555 dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY5555 dry syrup at 15 mg/kg
Trial: 8201768
Drug: SY5555 dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY5555 dry syrup (overall clinical efficacy)
Trial: 8201768
Drug: SY5555 dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY5555 dry syrup at daily doses of 12 - < 18 mg/kg
Trial: 8201768
Drug: SY5555 dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY5555 dry syrup at daily doses of 18 - < 27 mg/kg
Trial: 8201768
Drug: SY5555 dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY5555 dry syrup at daily doses of 27 - < 33 mg/kg
Trial: 8201768
Drug: SY5555 dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY5555 dry syrup (bacteriological eradication)
Trial: 2883952
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray of LHRH, 0.4 mg thrice daily during 28 consecutive days
Trial: 2883952
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray of LHRH, 0.4 mg twice daily on alternate days for 1 month
Trial: 2883952
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray of LHRH, 0.4 mg twice daily on alternate days for 3 months
Trial: 29731444
Drug: CSP 400mg
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSP 400mg + Metformin 600mg (DT1)
Trial: 29731444
Drug: Metformin 600mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 600mg (PC)
Trial: 26434382
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel group (3 mL 2% lidocaine gel applied to the cervix and intrauterine infusion of 5 mL normal saline)
Trial: 26434382
Drug: Lidocaine infusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine infusion group (3 mL gel lubricant applied to the cervix and intrauterine infusion of 5 mL 2% lidocaine)